<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989115</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-4630-02</org_study_id>
    <nct_id>NCT03989115</nct_id>
  </id_info>
  <brief_title>Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC</brief_title>
  <official_title>A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 With Osimertinib in Participants With EGFR Mutation Positive, Locally Advanced or Metastatic NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolution Medicines, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Revolution Medicines, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and&#xD;
      pharmacodynamic (PD) proﬁles of RMC-4630 and cobimetinib in adult participants with&#xD;
      relapsed/refractory solid tumors with specific genomic aberrations and to identify the&#xD;
      recommended Phase 2 dose (RP2D); and to evaluate the safety, tolerability, pharmacokinetic&#xD;
      (PK), and pharmacodynamic (PD) proﬁles of RMC-4630 and osimertinib in adult participants with&#xD;
      EGFR mutation-positive locally advanced or metastatic NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate&#xD;
      the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630&#xD;
      in combination with cobimetinib in participants with relapsed/refractory solid tumors; and of&#xD;
      RMC-4630 in combination with osimertinib in adult participants with EGFR mutation-positive&#xD;
      locally advanced or metastatic NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Incidence, nature, and severity of treatment-emergent AEs and SAEs, graded according to the NCI CTCAE v5 for the combination of RMC-4360 and cobimetinib or RMC-4360 and osimertinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence and nature of DLTs for the combination of RMC-4630 and cobimetinib or RMC-4360 and osimertinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Peak plasma concentration of RMC-4630 and cobimetinib or RMC-4360 and osimertinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to achieve peak plasma concentration of RMC-4630 and cobimetinib or RMC-4360 and osimertinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Area under the plasma concentration time curve of RMC-4630 and cobimetinib or RMC-4360 and osimertinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Elimination half-life of RMC-4630 and cobimetinib or RMC-4360 and osimertinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Ratio of accumulation of RMC-4630 and cobimetinib or RMC-4360 and osimertinib from a single dose to steady state with repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall response rate of RMC-4630 and cobimetinib or RMC-4360 and osimertinib per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of response of RMC-4630 and cobimetinib or RMC-4360 and osimertinib per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>RMC-4630 and Cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMC-4630 and Cobimetinib for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RMC-4630 and Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMC-4630 and Osimertinib for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-4630</intervention_name>
    <description>RMC-4630 for oral administration</description>
    <arm_group_label>RMC-4630 and Cobimetinib</arm_group_label>
    <arm_group_label>RMC-4630 and Osimertinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Cobimetinib for oral administration</description>
    <arm_group_label>RMC-4630 and Cobimetinib</arm_group_label>
    <other_name>GDC-0973, XL518</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Osimertinib</intervention_name>
    <description>Osimertinib for oral administration</description>
    <arm_group_label>RMC-4630 and Osimertinib</arm_group_label>
    <other_name>Tagrisso</other_name>
    <other_name>AZD9291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  For RMC-4630 + Cobimetinib only - Participants who have advanced solid tumors that&#xD;
             have failed, are intolerant to, or are considered ineligible for standard of care&#xD;
             anti-cancer treatments including approved drugs for oncogenic drivers in their tumor&#xD;
             type.&#xD;
&#xD;
          -  For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not&#xD;
             amenable to curative surgery or radiotherapy&#xD;
&#xD;
          -  For RMC-4630 + Cobimetinib only - Participants must have one of the following&#xD;
             genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or&#xD;
             NF1 LOF mutations&#xD;
&#xD;
          -  For RMC-4630 + Osimertinib only - Evidence of radiological documentation of&#xD;
             progression with osimertinib monotherapy or an osimertinib containing regimen.&#xD;
             Participants should not be considered a current candidate for 1st generation EGFR&#xD;
             TKI's by the investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤1&#xD;
&#xD;
          -  Adequate hematological, hepatic, and renal function&#xD;
&#xD;
          -  Capable of giving signed informed consent form (ICF). Willing and able to compile with&#xD;
             study requirements and restrictions&#xD;
&#xD;
          -  Life expectancy &gt;12 weeks&#xD;
&#xD;
          -  Female of childbearing potential and males with partners of childbearing potential&#xD;
             must comply with effective contraception criteria .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary central nervous system (CNS) tumors.&#xD;
&#xD;
          -  Known or suspected leptomeningeal or brain metastases or spinal cord compression.&#xD;
&#xD;
          -  For RMC-4630 + osimertinib arm only - Known or suspected Small cell, squamous, or&#xD;
             pleomorphic lung transformations&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Active, clinically signiﬁcant interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  History or current evidence of retinal pigment epithelial detachment (RPED), central&#xD;
             serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or&#xD;
             RVO&#xD;
&#xD;
          -  Known HIV infection or active/chronic hepatitis B or C infection.&#xD;
&#xD;
          -  Any other unstable or clinically signiﬁcant concurrent medical condition that would,&#xD;
             in the opinion of the investigator, jeopardize the safety of a participant, impact&#xD;
             their expected survival through the end of the study participation, and/or impact&#xD;
             their ability to comply with the protocol prior/concomitant therapy&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Revolution Medicines, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Revolution Medicines, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Francisco - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute, Franz Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Seton Medical Center at University of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists (Fairfax) - USOR</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHP2</keyword>
  <keyword>PTPN11</keyword>
  <keyword>NSCLC</keyword>
  <keyword>KRAS G12</keyword>
  <keyword>BRAF Class 3</keyword>
  <keyword>NF1 LOF</keyword>
  <keyword>KRAS amplification</keyword>
  <keyword>KRAS mutations</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>carcinoma, non-small-cell lung</keyword>
  <keyword>neoplasm, squamous cell</keyword>
  <keyword>carcinoma, squamous cell</keyword>
  <keyword>esophageal neoplasms carcinoma, bronchogenic</keyword>
  <keyword>bronchial neoplasms</keyword>
  <keyword>lung neoplasms</keyword>
  <keyword>respiratory tract neoplasms</keyword>
  <keyword>thoracic neoplasms</keyword>
  <keyword>neoplasms by site</keyword>
  <keyword>neoplasms</keyword>
  <keyword>lung diseases</keyword>
  <keyword>respiratory tract diseases</keyword>
  <keyword>gastrointestinal cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>skin cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>endometrium/uterus cancer</keyword>
  <keyword>cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

